LIGHTSITE II study: Photobiomodulation treatment improves vision in eyes with dry AMD
September 12th 2021During a presentation at the EURETINA 2021 Virtual Congress, Prof. Ben Burton detailed how dry AMD patients treated with photobiomodulation therapy have seen improvements in best-corrected visual acuity 9 months after treatment.
Brolucizumab injection improves vision in eyes with neovascular AMD
September 11th 2021In a presentation at the EURETINA 2021 Virtual Congress, Dr Cristina Cristian noted that an injection of brolucizumab treatment in patients with neovascular age-related macular degeneration led to a median improvement in visual acuity (VA) of 10.5 letters and the drug was well-tolerated.
Addressing roadblocks of treating peripheral hemorrhagic polypoidal choroidal vasculopathy
September 9th 2021Treating the disease can be a challenge, and at the EURETINA 2021 Virtual Congress, Dr Chekitaan Singh discussed a case study detailing the care of a patient who had already lost vision in one eye from a similar issue.
Autoimmune uveitis targeted by AAV gene therapy
September 8th 2021Investigators have found that 1 intravitreal injection of an adeno-associated virus encoding an immunosuppressive transgene, either HLA-G or eqIL-10, reduced the clinical and histologic inflammation in a well-established model of autoimmune uveitis.